Key result
LV summit PVCs linked to ~164% higher risk of non-ischemic cardiomyopathy.
Why the study?
Outflow tract PVCs have long been considered benign without pre-existing structural heart disease, but emerging evidence suggests they may manifest as an early sign of cardiomyopathy.
Does the anatomical location of outflow tract PVCs predict the development of new-onset cardiomyopathy in patients undergoing ablation?
Cohort (n=437)
Does the anatomical location of outflow tract PVCs predict the development of new-onset cardiomyopathy in patients undergoing ablation?
LV summit premature ventricular complexes are associated with a significantly increased risk of developing non-ischemic cardiomyopathy, suggesting they may serve as an early marker of underlying myocardial disease.
Answers are grounded in this paper and cite their sources.
May support enhanced cardiomyopathy surveillance in LV summit PVC patients; hypothesis-generating for location-specific risk stratification.
Background Premature ventricular complexes (PVCs) originating from ventricular outflow tracts have long been considered benign, particularly in the absence of pre-existing structural heart disease (SHD). However, emerging evidence suggests that outflow tract PVCs may also manifest as a first sign of cardiomyopathy. We aimed to assess the incidence of new-onset cardiomyopathy among patients with outflow tract PVCs and the impact of PVC site of origin on cardiomyopathy development. Objective To assess the incidence of new-onset cardiomyopathy and its association with PVC site of origin. Methods This retrospective study included all consecutive patients undergoing right or left ventricular outflow tract (RVOT/LVOT) PVC ablation between 2017-2025. PVC origin was defined by electroanatomical mapping. The primary outcome was new-onset cardiomyopathy. Secondary outcomes included PVC-induced and PVC-aggravated cardiomyopathy. Results Among 437 patients, 357 (81.7%) had no history of SHD at baseline. During a median follow-up of 5.1 (2.8–7.6) years, 25 patients (7.0%) without SHD at baseline developed non-ischemic cardiomyopathy. LV summit PVCs were independently associated with a higher risk of non-ischemic cardiomyopathy (adjusted OR 2.64 [1.36–5.27]; p<0.01). No PVC site of origin was associated with PVC-induced cardiomyopathy. In patients with pre-existing SHD, PVCs predominantly originated from the LVOT and were associated with limited ejection fraction recovery. Conclusion In this large retrospective study, LV summit PVCs were associated with an increased risk of non-ischemic cardiomyopathy — a hypothesis-generating finding suggesting they may represent an early manifestation of underlying myocardial disease. Future prospective studies are warranted to confirm this association and inform long-term surveillance strategies.
No takes yet. Share an insight, caveat, or question.
Cherbi et al. (2026) conducted a cohort in Outflow tract premature ventricular contractions (n=437). LV summit PVCs vs. Other outflow tract PVC origins was evaluated on New-onset cardiomyopathy (OR 2.64, 95% CI 1.36-5.27, p=<0.01). LV summit premature ventricular complexes were independently associated with a higher risk of non-ischemic cardiomyopathy.
Synapse has enriched 10 related papers. Consider them for comparative context: